Interface Biologics, Inc.
Presenter: Tom Reeves, President & CEO
Company Information
Company Type: Medical Technologies
Development Stage: Emerging
Company Profile
Interface Biologics Inc. (IBI) is a privately held early commercial stage company that develops transformative biomedical polymer technology to improve the safety and effectiveness of medical devices. Our primary technology focus areas are 1) anti-thrombogenic devices that reduce thrombosis without the need for heparin and 2) programmable combination drug delivery devices.
Intellectual Property
3 U.S. patents
13 patents pending
Investors
Interface Biologics is venture capital backed by Business Development Bank of Canada, VenGrowth Asset Management and Covington Capital.
Management Team
Thomas P. Reeves, President & CEO
Dr. Paul Santerre, Chief Scientific Officer
Bunmi Dosunmu, V.P. Finance
Mark Steedman, V.P. Business Development
Frank Shannon, V.P. Clinical & Regulatory Affairs
Dr. Roseita Esfand, Director R&D
Jeannette Ho, Director of Operations
Presenter Bio
Tom joined Interface Biologics in November of 2008 as President and Chief Executive Officer. Tom brings a wealth of experience in running different companies in a variety of industries through various stages of growth. Most recently, he was President and COO of OccuLogix, Inc. (NASDAQ: OCCX) a medical device company focused on age related eye disease where he was instrumental in their 2004 IPO which raised over $100 million. Prior to OccuLogix, Mr. Reeves was the President of Borderfree, an international e-commerce service provider which was sold to Canada Post in 2004. Previously, Mr. Reeves spent 12 years in the wholesale computer products industry in various senior positions including President of Merisel Canada and Managing Director of Merisel Europe. Mr. Reeves started his career with the Boston Consulting Group (BCG) in San Francisco. He holds a BA in Economics, magna cum laude, from Harvard University and an MA in International Relations from the Australian National University
Contact
Interface Biologics, Inc.
MaRS Centre, South Tower
101 College St., Suite 300
Toronto
ON, Canada
M5G 1L7
ph: 416-673-8168
fx: 416-977-1329
www.interfacebiologics.com
treeves@interfacebiologics.com